SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001104659-18-056032
Filing Date
2018-09-10
Accepted
2018-09-10 16:31:55
Documents
3
Period of Report
2018-07-23
Items
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A a18-27046_18ka.htm 8-K/A 41026
2 EX-99.3 a18-27046_1ex99d3.htm EX-99.3 295442
3 EX-99.4 a18-27046_1ex99d4.htm EX-99.4 341114
  Complete submission text file 0001104659-18-056032.txt   678812
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-37558 | Film No.: 181063124
SIC: 2834 Pharmaceutical Preparations